Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631
This examiner grants 36% of resolved cases
Nicholas Adam Humphries is a patent examiner in Tech Center 1600, where he serves in Art Unit 1631. He has resolved 36 cases during his tenure. His allowance rate is 36.1 percent, which indicates the frequency of successful outcomes for applications under his review. This 36.1 percent rate suggests that practitioners should be prepared for a challenging examination process in Art Unit 1631.
The data highlights an interview lift of 75.9 percent. This 75.9 percent lift is a substantial increase over the base allowance rate, suggesting that direct communication is a highly effective strategy for resolving rejections. For applications that are allowed, the median days to allowance is 1370. This 1370-day timeline provides a specific expectation for the duration of the prosecution process from filing to grant. By combining the 36 resolved cases with the 75.9 percent interview lift, practitioners can conclude that interviews are a vital tool for navigating this examiner's requirements.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17774834 | EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18009071 | PROCESS FOR PRODUCING CARRIER PARTICLES FOR THE CULTIVATION OF BIOLOGICAL CELLS, CARRIER PARTICLES AND THEIR USE | Non-Final OA | Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V. |
| 18084105 | METHOD FOR REDUCING OFF-TARGET UPTAKE OR ACCUMULATION OF AGENTS | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18350986 | CELLS AND METHOD OF CELL CULTURE | Final Rejection | Pfizer Inc. |
| 18262799 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Final Rejection | The Trustees of Indiana University |
| 18246087 | NOVEL ENHANCED BASE EDITING OR REVISING FUSION PROTEIN AND USE THEREOF | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18718990 | THERAPY FOR HEPATIC DISORDERS USING ADIPOSE-DERIVED MESENCHYMAL STEM CELL LINE | Non-Final OA | Keio University |
| 18042726 | VIRAL VECTORS ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES | Final Rejection | The Trustees of the University of Pennsylvania |
| 17641254 | EX VIVO LYMPH NODE AND USES THEREOF | Non-Final OA | UNIVERSITY OF DELAWARE |
| 18170296 | COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | Non-Final OA | The University of Hong Kong |
| 17632063 | TARGETED GENE THERAPY TO TREAT NEUROLOGICAL DISEASES | Non-Final OA | Cornell University |
| 18361790 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF IMMUNE CELLS | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18266951 | CULTURE MATERIAL AND USE THEREOF | Final Rejection | MITSUI CHEMICALS, INC. |
| 18286709 | RATIONAL POLYPLOID AAV VIRIONS THAT CROSS THE BLOOD BRAIN BARRIER AND ELICIT REDUCED HUMORAL RESPONSE | Non-Final OA | ASKBIO INC. |
| 17907229 | INDUCIBLE PROMOTER FOR VIRAL VECTOR PRODUCTION | Final Rejection | ASKBIO INC. |
| 17764413 | BCL11A GUIDE AND BASE EDITOR DELIVERY | Non-Final OA | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 17995609 | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | Final Rejection | FIGENE, LLC |
| 18685905 | Use Of Chemokine Receptors In Cellular Homing | Non-Final OA | CarryGenes Bioengineering, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy